HemaCare Reports Strong First Half 2017 Results
(Los Angeles – August 21, 2017) HemaCare Corporation (OTCBB: HEMA), HemaCare Corporation today reported financial results for the six months ended June 30, 2017, showing continued robust gains in revenue, gross profit, and net income compared to the same period of 2016. 1H1Revenue from operations grew 50% to $8.7 million, while gross profit of $4.5 million (52% of sales) increased by 53% compared to the same period in 2016 (51% of sales). Net income increased to $552,000, versus a prior year loss. For complete unaudited June 30, 2017 Financial Statements, please click here.
Pete van der Wal, HemaCare’s President and Chief Executive, stated “HemaCare continues to strengthen our leadership position as a critical supplier to customers performing cell therapy research, process development, and commercialization. Our portfolio of products and services includes leukapheresis patient collections for autologous cell therapy processing, which leads to the use of patients’ own cells to fight disease. Additionally, we provide superior leukapheresis starting material from a highly characterized, recallable donor pool, which is critical when manufacturing off-the-shelf allogeneic therapy products. ”
He further stated “We have secured long term access to a state of the art facility allowing HemaCare to optimize process flow, utilize flexible production environments to serve our customers’ increasingly complex requirements, and provide sufficient scalability to support the increasing demand of our global customer base.”